NetworkNewsBreaks – Inovio Pharmaceuticals, Inc. (NASDAQ: INO) to Host Expert Call on Coronavirus Implications Both Near its Source and Closer to Home

January 29, 2020 12:06:11

Inovio Pharmaceuticals (NASDAQ: INO) was featured in a recent Equity Research Report Published by Roth Capital Partners, LLC. According to the update, the company intends to host a conference call at 10:30 a.m. EST on Monday, February 3, 2020, during which Dr. David B. Weiner, Ph.D. will discuss implications of the coronavirus epidemic both near its source and closer to home, given the recent outbreak of a new strain in China and its spread to North America. Dr Weiner is executive vice president of the Wistar Institute, director of Vaccine & Immunotherapy Center, and professor emeritus at the University of Pennsylvania School of Medicine. He directs a translational molecular immunology research team that is focused on creating novel immunotherapy approaches for disease prevention and treatment using synthetic nucleic acid technology. The team’s accomplishments include the first clinical studies of DNA vaccines and work that has revitalized the field, rapidly and safely moving new advances into human studies. These include, among others, the world’s first Zika vaccine, the first MERS vaccine, as well as advanced and novel vaccines for Ebola and HIV.

To view the full report, visit

About Inovio Pharmaceuticals

Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure and/or protect people from diseases associated with HPV, cancer, and infectious diseases. Inovio is the first and only company to have clinically demonstrated that a DNA medicine can be delivered directly into cells in the body via a proprietary smart device to safely produce a robust immune response to destroy and clear high-risk HPV 16 and 18, which are responsible for 70% of cervical cancer, 90% of anal cancer and 69% of vulvar cancer. In addition to HPV, Inovio’s optimized plasmid design and delivery technology has been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. Inovio’s most advanced clinical program, VGX-3100, is in Phase 3 development for the treatment of HPV-related cervical pre-cancer. Also in development are Phase 2 immuno-oncology programs targeting HPV-related cancers and GBM, as well as externally funded platform development programs in Zika, MERS, Lassa, and HIV. Partners and collaborators include ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency, GeneOne Life Science, HIV Vaccines Trial Network, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Regeneron, Roche/Genentech, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. For more information, visit the company’s website at

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire is part of the InvestorBrandNetwork.